for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Cumberland Pharmaceuticals, Inc.

CPIX.O

Latest Trade

2.23USD

Change

-0.05(-2.20%)

Volume

21,895

Today's Range

2.20

 - 

2.26

52 Week Range

2.20

 - 

3.94

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
2.28
Open
2.24
Volume
21,895
3M AVG Volume
0.82
Today's High
2.26
Today's Low
2.20
52 Week High
3.94
52 Week Low
2.20
Shares Out (MIL)
14.81
Market Cap (MIL)
33.02
Forward P/E
--
Dividend (Yield %)
--

Next Event

Q4 2021 Cumberland Pharmaceuticals Inc Earnings Release

Latest Developments

More

Cumberland Pharmaceuticals Posts Q3 Loss Per Share Of $0.07

Cumberland Pharmaceuticals Posts Q2 EPS Of $0.08

Cumberland Pharmaceuticals Names John Hamm New CFO

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Cumberland Pharmaceuticals, Inc.

Cumberland Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the acquisition, development and commercialization of prescription products. The Company's product portfolio includes Acetadote (acetylcysteine) Injection, for the treatment of acetaminophen poisoning; Caldolor (ibuprofen) Injection, for the treatment of pain and fever; Kristalose (lactulose) for Oral Solution, a prescription laxative, for the treatment of chronic and acute constipation; Omeclamox Pak, (omeprazole, clarithromycin, amoxicillin) for the treatment of Helicobacter pylori (H. pylori) infection and related duodenal ulcer disease; Vaprisol (conivaptan) Injection, to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia; Vibativ (telavancin) Injection, for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections; and RediTrex.

Industry

Biotechnology & Drugs

Contact Info

2525 W End Ave Ste 950

NASHVILLE, TN

37203-1608

United States

+1.615.2550068

http://www.cumberlandpharma.com/

Executive Leadership

A. J. Kazimi

Chairman of the Board, Chief Executive Officer

John Hamm

Chief Financial Officer, Director Finance and Accounting

Martin E. Cearnal

Executive Vice President, Chief Commercial Officer, Director

Leo B. Pavliv

Executive Vice President - Operations, Chief Development Officer

James L. Herman

Senior Vice President, Chief Compliance Officer

Key Stats

3.00 mean rating - 1 analysts
Sell
Hold
Buy
Price To Earnings (TTM)
--
Price To Sales (TTM)
0.87
Price To Book (MRQ)
0.71
Price To Cash Flow (TTM)
18.81
Total Debt To Equity (MRQ)
32.04
LT Debt To Equity (MRQ)
32.04
Return on Investment (TTM)
-4.22
Return on Equity (TTM)
-3.27

Latest News

Latest News

BRIEF-Cumberland Posts Q1 Adjusted EPS Of $0.01

* CUMBERLAND PHARMACEUTICALS REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS & COMPANY UPDATE

BRIEF-To Help Prepare For The Covid-19 Patient Surge Cumberland Pharmaceuticals Expands Availability Of Vaprisol® To Treat Hyponatremia In Critical Care Units

* TO HELP PREPARE FOR THE COVID-19 PATIENT SURGE CUMBERLAND PHARMACEUTICALS EXPANDS AVAILABILITY OF VAPRISOL® TO TREAT HYPONATREMIA IN CRITICAL CARE UNITS Source text for Eikon: Further company coverage:

BRIEF-Cumberland To Expand Availability Of Caldolor For High Fever Associated With Coronavirus

* CUMBERLAND PHARMACEUTICALS ANNOUNCES INITIATIVE TO EXPAND AVAILABILITY OF CALDOLOR® TO HELP TREAT HIGH FEVERS ASSOCIATED WITH CORONAVIRUS INFECTIONS

BRIEF-Cumberland Pharmaceuticals Inc - Initiative Designed To Help Address Potential Antibiotic Shortages

* CUMBERLAND PHARMACEUTICALS ANNOUNCES INITIATIVE TO EXPAND AVAILABILITY OF VIBATIV® TO TREAT HOSPITAL-ACQUIRED & VENTILATOR-ASSOCIATED PNEUMONIA RESULTING FROM CORONAVIRUS INFECTIONS

BRIEF-Cumberland Pharmaceuticals Reports 17% Revenue Growth For The Full Year 2019

* CUMBERLAND PHARMACEUTICALS REPORTS 17% REVENUE GROWTH FOR THE FULL YEAR 2019

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up